Barbara Grün
6 Papers
Barbara Grün is an academic researcher. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 3, co-authored 4 publications.
Chat about Author
Papers
Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer - The PICCASSO phase I trial.
Georg Martin Haag,Christoph Springfeld,Barbara Grün,Leonidas Apostolidis,Stefanie Zschäbitz,Mareike Dietrich,Anne Berger,Tim Frederik Weber,Inka Zoernig,Marina Schaaf,Lisa Waberer,D. W. Müller,Salah-Eddin Al-Batran,Niels Halama,Dirk Jaeger +14 more
TL;DR: PICCASSO as mentioned in this paper is a phase I trial exploring safety and efficacy of pembrolizumab and maraviroc in refractory mismatch repair proficient (MMRp) colorectal cancer.
65
Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy
Thomas Walle,Sunanjay Bajaj,Joscha A. Kraske,T. Rösner,Christiane S Cussigh,Katharina A. Kälber,L. J. Müller,S.B. Strobel,Jana Burghaus,Stefan M. Kallenberger,Christoph Stein-Thöringer,Maximilian Jenzer,Antonia Schubert,Steffen Kahle,Anja Williams,Birgit Hoyler,Lin Zielske,Renate Skatula,Stefanie Sawall,Mathias F. Leber,Russell Kunes,Johannes Krisam,Carlo Fremd,Andreas Schneeweiss,Jürgen Krauss,Leonidas Apostolidis,Anne Berger,Georg Martin Haag,Stefanie Zschäbitz,Niels Halama,Christoph Springfeld,Jessica C. Hassel,Dirk Jäger,Omar Abdelrahim,Elena Busch,Patrick Derigs,Katharina Dischinger,Fouad Mitri,Kerstin Schmidt,Irfan A. Bhatti,Barbara Grün,Nicolas Hohmann,Lena Woydack,Xin-Wen Zhang,Dyke Ferber,Andreas Mock,Tillmann Pompecki,Timo Schank,Guy Ungerechts +48 more
TL;DR: In this paper , adverse events and serum cytokines in patients with 23 different tumors undergoing or not undergoing COVID-19 vaccination under ICI therapy in a prospectively planned German single-center cohort study (n = 220).
Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma—a phase II trial of the AIO study group (AIO STO 0321)
Joseph Tintelnot,Alexander Stein,Salah-Eddin Al-Batran,T. Ettrich,Thorsten Götze,Barbara Grün,G. M. Haag,Vera Heuer,R. Hofheinz,Nils Homann,Tobias S Bröring,Annika Kurreck,Sylvie Lorenzen,Nicolas Moosmann,Christian Müller,M. Schuler,Gabriele Margareta Siegler,Mascha Binder,Eray Gökkurt +18 more
TL;DR: The PHERFLOT study is an open-label, single-arm, multicenter, exploratory phase II trial designed to assess the efficacy, safety, and tolerability of perioperative pembrolizumab, FLOT, and trastuzumab in patients with previously untreated localized HER2-positive EGA.
4
Interprofessional evidence-based counselling programme for complementary and integrative healthcare in patients with cancer: study protocol for the controlled implementation study CCC-Integrativ
Jan Valentini,Daniel Fröhlich,Regina Stolz,Cornelia Mahler,Peter Martus,Nadja Klafke,Markus Horneber,Jona Frasch,Klaus Kramer,Hartmut Bertz,Barbara Grün,Katrin Tomaschko-Ubeländer,Stefanie Joos +12 more
TL;DR: An evidence-based interprofessional counselling programme on CIH will be implemented at four Comprehensive Cancer Centres in the federal state of Baden-Wuerttemberg, Germany and an intensive online training programme, a CIH knowledge database and an interprofessional team-building process were developed and implemented.
Tailored immunotherapy approach with nivolumab in advanced transitional cell carcinoma (TITAN-TCC).
Marc-Oliver Grimm,Bernd J. Schmitz-Dräger,Uwe Zimmermann,Barbara Grün,Gustavo Baretton,Marc Schmitz,Susan Foller,Martin Schostak,Friedemann Zengerling,U. Schumacher,Wolfgang Loidl,Johannes Meran +11 more
TL;DR: In first line, this significantly improved ORR compared to the expected response rate of Nivo monotherapy, providing further evidence to the added value of Ipi in combination with Nivo.